Dyslipidemia and the vulnerable plaque

被引:27
作者
Farmer, JA
Gotto, AM
机构
[1] Cornell Univ, Weill Med coll, New York, NY 10021 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
关键词
D O I
10.1053/pcad.2002.123474
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the last decade, an increasingly sophisticated understanding of the pathogenesis of atherosclerosis and its cardiovascular consequences has emerged. The characteristics of the unstable atherosclerotic plaque, the substrate for the majority of acute coronary events, have been well defined: mild-to-moderate stenosis, a lipid-rich pool, few smooth muscle cells, a friable fibrous cap, and macrophage infiltration. Lipid modification, an important cardiovascular risk reduction strategy, induces a number of effects at the vascular level that may contribute to the clinical benefits seen in large-scale, prospective prevention trials. New developments in imaging technologies may afford improved opportunities to visualize the atrisk plaque and may provide new insights into the optimal management of the unstable plaque. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:415 / 428
页数:14
相关论文
共 68 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]   Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors [J].
Alfon, J ;
Guasch, JF ;
Berrozpe, M ;
Badimon, L .
ATHEROSCLEROSIS, 1999, 145 (02) :325-331
[3]   Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: An angioscopic study [J].
Asakura, M ;
Ueda, Y ;
Yamaguchi, O ;
Adachi, T ;
Hirayama, A ;
Hori, M ;
Kodama, K .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) :1284-1288
[4]   Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy [J].
Aviram, M ;
Hussein, O ;
Rosenblat, M ;
Schlezinger, S ;
Hayek, T ;
Keidar, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (01) :39-45
[5]   Tissue tartar as a therapeutic target coronary syndromes [J].
Banai, S ;
Gertz, SD .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (06) :763-+
[6]  
Behar S, 1999, Blood Coagul Fibrinolysis, V10 Suppl 1, pS41
[7]   Statins and fibrinogen [J].
Black, DM .
LANCET, 1998, 351 (9113) :1430-1430
[8]   HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells [J].
Bourcier, T ;
Libby, P .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :556-562
[9]   ATTENUATION OF THE SYNTHESIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY NIACIN - A POTENTIAL LINK BETWEEN LIPID-LOWERING AND FIBRINOLYSIS [J].
BROWN, SL ;
SOBEL, BE ;
FUJII, S .
CIRCULATION, 1995, 92 (04) :767-772
[10]   Thermal detection of cellular infiltrates in living atherosclerotic plaques: Possible implications for plaque rupture and thrombosis [J].
Casscells, W ;
Hathorn, B ;
David, M ;
Krabach, T ;
Vaughn, WK ;
McAllister, HA ;
Bearman, G ;
Willerson, JT .
LANCET, 1996, 347 (9013) :1447-1449